{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:35:44Z","timestamp":1793291744862,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012232","name":"National Key Clinical Specialty Discipline Construction Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012232","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism Open"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.metop.2026.100453","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T16:08:43Z","timestamp":1771517323000},"page":"100453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Baseline metabolite profiles predict the glucose-lowering efficacy of exenatide in patients with type 2 diabetes"],"prefix":"10.1016","volume":"29","author":[{"given":"Yunyi","family":"Le","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haining","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5744-5129","authenticated-orcid":false,"given":"Tianpei","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.metop.2026.100453_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/ndt\/gfaf177","article-title":"IDF diabetes atlas 11th edition 2025: global prevalence and projections for 2050","volume":"41","author":"Duncan","year":"2026","journal-title":"Nephrol Dial Transplant"},{"issue":"7258","key":"10.1016\/j.metop.2026.100453_bib2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.metop.2026.100453_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00125-024-06254-w","article-title":"Glycaemic control is still central in the hierarchy of priorities in type 2 diabetes management","volume":"68","author":"Khunti","year":"2025","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.metop.2026.100453_bib4","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.7326\/M23-0442","article-title":"Achievement of guideline-recommended targets in diabetes care in China : a nationwide cross-sectional study","volume":"176","author":"Zhong","year":"2023","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.metop.2026.100453_bib5","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab"},{"issue":"10","key":"10.1016\/j.metop.2026.100453_bib6","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1038\/s41591-025-03978-z","article-title":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","volume":"31","author":"McGowan","year":"2025","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"10.1016\/j.metop.2026.100453_bib7","first-page":"S73","article-title":"8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.metop.2026.100453_bib8","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3390\/jcm8030393","article-title":"Current progress in pharmacogenetics of second-line antidiabetic medications: towards precision medicine for type 2 diabetes","volume":"8","author":"Heo","year":"2019","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.metop.2026.100453_bib9","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrd.2016.32","article-title":"Emerging applications of metabolomics in drug discovery and precision medicine","volume":"15","author":"Wishart","year":"2016","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"10.1016\/j.metop.2026.100453_bib10","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2217\/pgs.15.20","article-title":"Pharmacometabonomics in humans: a new tool for personalized medicine","volume":"16","author":"Everett","year":"2015","journal-title":"Pharmacogenomics"},{"issue":"7","key":"10.1016\/j.metop.2026.100453_bib11","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3390\/molecules22071173","article-title":"Novel applications of metabolomics in personalized medicine: a mini-review","volume":"22","author":"Li","year":"2017","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.metop.2026.100453_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2020.107797","article-title":"Non-targeted metabolomic analysis predicts the therapeutic effects of exenatide on endothelial injury in patients with type 2 diabetes","volume":"35","author":"Yang","year":"2021","journal-title":"J Diabet Complicat"},{"issue":"8","key":"10.1016\/j.metop.2026.100453_bib13","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s00592-020-01510-y","article-title":"Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial","volume":"57","author":"Yang","year":"2020","journal-title":"Acta Diabetol"},{"issue":"1","key":"10.1016\/j.metop.2026.100453_bib14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00592-010-0220-6","article-title":"Evaluation of the efficacy and tolerability of miglitol in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylureas","volume":"48","author":"Hsieh","year":"2011","journal-title":"Acta Diabetol"},{"issue":"2","key":"10.1016\/j.metop.2026.100453_bib15","doi-asserted-by":"crossref","first-page":"376","DOI":"10.2337\/diacare.25.2.376","article-title":"Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients","volume":"25","author":"Yang","year":"2002","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.metop.2026.100453_bib16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1089\/152091503763816445","article-title":"Addition of rosiglitazone to existing sulfonylurea treatment in chinese patients with type 2 diabetes and exposure to hepatitis B or C","volume":"5","author":"Zhu","year":"2003","journal-title":"Diabetes Technol Therapeut"},{"issue":"4","key":"10.1016\/j.metop.2026.100453_bib17","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2337\/dc09-1488","article-title":"Costs and consequences associated with newer medications for glycemic control in type 2 diabetes","volume":"33","author":"Sinha","year":"2010","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.metop.2026.100453_bib18","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1185\/03007995.2011.590127","article-title":"GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials","volume":"27","author":"Esposito","year":"2011","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"10.1016\/j.metop.2026.100453_bib19","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00592-020-01660-z","article-title":"High baseline FGF21 levels are associated with poor glucose-lowering efficacy of exenatide in patients with type 2 diabetes","volume":"58","author":"Yang","year":"2021","journal-title":"Acta Diabetol"},{"issue":"2","key":"10.1016\/j.metop.2026.100453_bib20","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2337\/dc15-0258","article-title":"Markers of \u03b2-cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes","volume":"39","author":"Jones","year":"2016","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.metop.2026.100453_bib21","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1111\/dom.14463","article-title":"Comparable efficacy and safety between LY2963016 insulin glargine and insulin glargine (Lantus) in Chinese patients with type 1 diabetes: a phase III, randomized, controlled trial","volume":"23","author":"Yan","year":"2021","journal-title":"Diabetes Obes Metabol"},{"issue":"1","key":"10.1016\/j.metop.2026.100453_bib22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.metabol.2011.05.007","article-title":"Higher ratio of triglyceride to high-density lipoprotein cholesterol may predispose to diabetes mellitus: 15-year prospective study in a general population","volume":"61","author":"He","year":"2012","journal-title":"Metabolism"},{"issue":"9","key":"10.1016\/j.metop.2026.100453_bib23","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/dom.12932","article-title":"Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity","volume":"19","author":"Blundell","year":"2017","journal-title":"Diabetes Obes Metabol"},{"issue":"12","key":"10.1016\/j.metop.2026.100453_bib24","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat Rev Endocrinol"},{"issue":"11","key":"10.1016\/j.metop.2026.100453_bib25","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S2213-8587(23)00159-6","article-title":"Understanding diabetes heterogeneity: key steps towards precision medicine in diabetes","volume":"11","author":"Leslie","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.metop.2026.100453_bib26","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1021\/acs.jproteome.9b00319","article-title":"Prepregnant obesity of mothers in a multiethnic cohort is associated with cord blood metabolomic changes in offspring","volume":"19","author":"Schlueter","year":"2020","journal-title":"J Proteome Res"},{"issue":"2","key":"10.1016\/j.metop.2026.100453_bib27","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/dom.14891","article-title":"Effect of faecal microbial transplant via colonoscopy in patients with severe obesity and insulin resistance: a randomized double-blind, placebo-controlled phase 2 trial","volume":"25","author":"Ghorbani","year":"2023","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.metop.2026.100453_bib28","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cca.2022.12.019","article-title":"Serum metabolomics identified metabolite biomarkers and distinguished maturity-onset diabetes of the young from type 1 diabetes in the Chinese population","volume":"539","author":"Liu","year":"2023","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.metop.2026.100453_bib29","article-title":"Metabolomics uncovers the diabetes metabolic network: from pathophysiological mechanisms to clinical applications","volume":"16","author":"Xu","year":"2025","journal-title":"Front Endocrinol"}],"updated-by":[{"DOI":"10.1016\/j.metop.2026.100521","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:00:00Z","timestamp":1793232000000}}],"container-title":["Metabolism Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589936826000125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589936826000125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:24:41Z","timestamp":1777634681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589936826000125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":29,"alternative-id":["S2589936826000125"],"URL":"https:\/\/doi.org\/10.1016\/j.metop.2026.100453","relation":{},"ISSN":["2589-9368"],"issn-type":[{"value":"2589-9368","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baseline metabolite profiles predict the glucose-lowering efficacy of exenatide in patients with type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Metabolism Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metop.2026.100453","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100453"}}